about
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of SchistosomiasisSubstituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylasesEvolutionary relationships among protein lysine deacetylases of parasites causing neglected diseases.Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).Muscle Carnitine Palmitoyltransferase II Deficiency: A Review of Enzymatic Controversy and Clinical FeaturesKATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.Enantiomerically Pure 2-Methyltetrahydro-3-benzazepin-1-ols Selectively Blocking GluN2B Subunit Containing N-Methyl-D-aspartate Receptors.Analysis of the Resistance of Hepatitis C Virus NS5B Polymerase Inhibitors via Docking and Molecular Dynamics Simulation.Identification and Structure-Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1.Mind the methyl: methyllysine binding proteins in epigenetic regulation.Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum.Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.Homology modeling of parasite histone deacetylases to guide the structure-based design of selective inhibitors.Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives.Peptide backbone conformation affects the substrate preference of protein arginine methyltransferase I.Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B-Selective NMDA Receptor Antagonists with a Benzo[7]annulen-7-amine Scaffold.Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments.A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing.Photochromic histone deacetylase inhibitors based on dithienylethenes and fulgimides.Stereospecific capillary electrophoresis assays using pentapeptide substrates for the study ofAspergillus nidulansmethionine sulfoxide reductase A and mutant enzymesPyrido- and benzisothiazolones as inhibitors of histone acetyltransferases (HATs)Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptorsA novel non-phenolic dibenzazecine derivative with nanomolar affinities for dopamine receptorsEpigenetic small molecule modulators of histone and DNA methylation
P50
Q27704217-3E9B57C4-394E-464A-82D0-8AF8F25CB2F8Q27704244-47F39E51-762C-4C31-8E1D-7035BBDB69E1Q30313170-16469EA6-9F54-4DCA-94FC-1ABAFAE149C6Q30313275-48F65ACC-A5D4-49C1-87BD-3E70F6159E45Q30313571-98BCCCAC-BCC2-43E0-93D1-53CAB39CF70DQ30315861-4FFAD74E-5574-4094-97A3-7E8827489546Q30315990-EEDC3CB1-3815-4086-853E-8CFA86C4C5C2Q30316270-EEFB4AB5-1EE1-4E99-AB98-6EA07CDE0EF8Q30316361-52A97B0D-241F-4674-80DE-8919B0E0A3FCQ30316803-37A15A54-8189-4F3D-822A-55CBB53851C5Q36135192-11A43CC9-4929-4CEE-B064-9F8E6FB9E8B3Q38180674-9647A6C6-A8D6-4D48-BA3A-EAE6705226D8Q38723552-17E9559D-A1E8-40CD-A26E-B0563C6FA189Q38752778-FF816F60-EE5F-479B-A416-F2183996212BQ39735828-85E28A4A-2AB1-4B97-88FF-626AEEB75AA1Q40899864-39079173-B1B0-4D27-B1A6-EEC17CA8AD2EQ42727088-22602335-16D1-4392-BC6F-EE66657CEC9EQ45806981-21F336A4-3B71-4CB5-AEEB-C30EC861D726Q47347473-C81F7334-2351-4505-A339-19FFF383FBA7Q48021684-0D927FA2-D881-45D0-91A1-4C382B369ADCQ49383869-7FA23961-2A12-4984-9E8D-959918BFF580Q49786392-76F5A01D-09DA-4921-A740-93E0552A3C52Q50248874-CF31CF1B-7FC4-436D-A0E6-C309EDADAD47Q52677297-2184006C-A636-4F1E-9FD0-A3F550DF05DEQ53272199-29B3A64C-3631-4B5F-8201-9DB5A67762DEQ58860042-C2EC33AD-9D27-4222-AC51-E5B93C5D6733Q58860060-6EC7C071-8DFB-4D57-BBD7-85C840320A01Q83147979-0EE9FB80-DECD-48F1-9FA8-E48E55829DFCQ83612916-32E56E67-C491-4716-93E4-9A2CC92CEB82Q88176602-CEBB9520-F161-4B2D-B36E-3174649230C7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dina Robaa
@ast
Dina Robaa
@en
Dina Robaa
@es
Dina Robaa
@nl
Dina Robaa
@sl
type
label
Dina Robaa
@ast
Dina Robaa
@en
Dina Robaa
@es
Dina Robaa
@nl
Dina Robaa
@sl
prefLabel
Dina Robaa
@ast
Dina Robaa
@en
Dina Robaa
@es
Dina Robaa
@nl
Dina Robaa
@sl
P214
P106
P1153
35759379300
P214
P31
P496
0000-0003-4297-8130
P7859
viaf-173229061